Elena Rondi

Elena Rondi

Auto-generated profile, based on publicly available information

Elena Rondi

Department of Medical Physics, European Institute of Oncology, Milan, Italy

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
PDF file
DADaniela Alterio
Daniela Alterio
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
BFBenedetta Franchi
Benedetta Franchi
AOAlberto d Onofrio
Alberto d Onofrio
VPValeria Piazzi
Valeria Piazzi
RORoberto Orecchia
Roberto Orecchia

1 August 2017 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
Giuseppe FanettiGiuseppe Fanetti
Giuseppe Fanetti
CFCristiana Fodor
Cristiana Fodor
DCDelia Ciardo
Delia Ciardo
LSLuigi Santoro
Luigi Santoro
RORoberto Orecchia
Roberto Orecchia

1 February 2019 in British Journal of Radiology
Verified
Journal Article
Closed access
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
DRDamaris Patricia Rojas
Damaris Patricia Rojas
DZDario Zerini
Dario Zerini
CFCristiana Fodor
Cristiana Fodor
AVAnna Viola
Anna Viola
DCDelia Ciardo
Delia Ciardo
To evaluate high-precision external beam reirradiation (re-EBRT) for local relapse of prostate cancer (PCa) after radiotherapy. This retrospective study included patients with biochemical failure and evidence of isolated local recurrence of PCa after radical/salvage EBRT or brachytherapy that received salvage stereotactic body radiation therapy (SBRT, re-EBRT). Biopsy was not mandatory if all diagnostic elements were univocal (prostate specific antigen evolution, choline-positron emission tomography or magnetic resonance imaging). Salvage SBRT (re-EBRT) was delivered with image-guided radiation therapy (RapidArc®, VERO® and CyberKnife®). Data of 64 patients were included, median age at salvage SBRT was 73.2 years, median pre-salvage SBRT prostate specific antigen was 3.89 ng ml-1 . Median total dose was 30 Gy in five fractions, biologically effective dose (BED) of 150 Gy. One acute G3 genitourinary event and one late G3 genitourinary event were observed. No G ≥ 3 bowel toxicity was registered. At the median follow-up of 26.1 months, tumor progression was observed in 41 patients (64%). 18 patients (28%) experienced local relapse. 2-year local control, biochemical and clinical relapse free survival rates were 75, 40 and 53%, respectively. With BED ≥130 Gy 1-year biochemical and clinical progression-free survival rate were 85 and 90%, respectively. Salvage SBRT (re-EBRT) for isolated local PCa recurrence is a safe, feasible and noninvasive salvage treatment. Further investigation is warranted to define the optimal patient selection, dose and volume parameters. Salvage SBRT reirradiation for the locally recurrent PCa offer a satisfactory tumor control and excellent toxicity profile, if BED ≥130 Gy is administered.

1 December 2003 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MCMario Ciocca
Mario Ciocca
RORoberto Orecchia
Roberto Orecchia
CGCristina Garibaldi
Cristina Garibaldi
ERElena Rondi
Elena Rondi
ALAlberto Luini
Alberto Luini
UVUmberto Veronesi
Umberto Veronesi


1 January 2005 in British Journal of Radiology
Verified
Journal Article
Closed access
ROR Orecchia
R Orecchia
AHA Huscher
A Huscher
MLM C Leonardi
M C Leonardi
RGR Gennari
R Gennari
VGV Galimberti
V Galimberti
SFS Franzetti
S Franzetti
Recent data show that axillary coverage can be obtained, but only through a selective CT-based treatment planning, as standard tangential fields are inadequate to deliver therapeutic doses. Currently, the replacement of axillary dissection with new techniques, such as sentinel node (SN) biopsy, makes it necessary to re-address the question about the real role of axillary irradiation, complicated by the differences in the anatomy of dissected and undissected axillary regions. The purpose of this paper is the dosimetric analysis of first axillary level coverage in standard irradiation of 15 breast-cancer patients treated with quadrantectomy and SN biopsy (negative finding). During surgery a clip on the site of the SN was positioned, marking the caudal margin of first axillary level. After the breast treatment plan was completed, the first axillary level was contoured on CT scans, from the site of the surgical clip up to the sternal manubrium, for coverage analysis with dose-volume histograms (DVHs) and three-dimensional isodose visualization. The maximum dose mean ranged from 5% to 80% of the prescribed dose (mean value 48.7%). The mean total dose received by the volume of interest was lower than 40 Gy in all but one patient. No patient had total irradiation of first nodal level; only one patient had 35% of the volume enclosed in the 100% isodose. Our analysis lead to the conclusion that therapeutic doses are not really delivered to first level axillary level nodes by a standard tangential field technique, and that specific treatment planning and beam arrangement are required when adequate coverage is necessary.